• CorMedix Inc. to Present at the Cantor Global Healthcare Conference

    Source: Nasdaq GlobeNewswire / 13 Sep 2024 07:30:00   America/Chicago

    BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.

    Cantor Global Healthcare Conference

    Date: Thursday, September 19, 2024
    Time: 10:55AM EDT
    Format: Fireside Chat and 1x1 Meetings
    Webcast: Click Link
       

    A replay of the fireside chat will also be available in the “Events and Presentations” page on the investor relations portion of the Company’s website at: www.cormedix.com

    About CorMedix

    CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

    Investor Contact:
    Dan Ferry
    Managing Director
    LifeSci Advisors
    daniel@lifesciadvisors.com
    (617) 430-7576


    Primary Logo

Share on,